US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

42.61

+0.93212.24%

Post-market: 42.680.0729+0.17%16:10 EDT

Volume:561

Turnover:23.88K

Market Cap:118.32M

PE:- -

High:42.68

Open:42.52

Low:42.52

Close:41.68

52wk High:48.78

52wk Low:29.44

Shares:2.78M

Float Shares:2.78M

Volume Ratio:0.36

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Teva announces FDA approval for Weltruza

Guardant announces Europe approval of Guardnat360 CDx as Etcamaha companion

Guardant Health Wins EU CE Mark for Guardant360 CDx as Camizestrant Companion Diagnostic in ER-Positive Breast Cancer

Guardant Health Announces Approval in Europe of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Er-Positive Breast Cancer

THOMSON REUTERS

Guardant Health to Report Q3 2026 Financial Results After Market Close, Host Conference Call

Is Spyre Therapeutics (SYRE) Fully Priced Following Its $350 Million Equity Raise?

Simply Wall St.

Novartis announces FDA approval of Rhapsido for symptomatic dermographism

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

Guardant Health is Maintained at Overweight by Barclays

LivaNova Price Target Announced at $105.00/Share by Barclays

StemRIM Wins U.S. Patent for Stem Cell Gene Therapy Targeting Rare Skin Disease

Should New FILSPARI Data Require Action From Travere Therapeutics Stock Investors?

Simply Wall St.

LivaNova initiated with an Overweight at Barclays

Update: Spyre Shares Fall After Pricing $350 Million Stock Offering

MT Newswires Live

Guardant Health Inc Stock (GH) Moved Down by 8.27% on Oct 6: What Investors Need To Know

Guggenheim Remains a Buy on Cogent Biosciences (COGT)

Spyre Therapeutics falls -8.4%

U.S. Stocks on the MOVE-MYR Group, Spyre Therapeutics, AMD

Spyre Therapeutics Slips on $350 Mln Share Sale

Spyre Therapeutics Shares Slip 1.7% Premarket After Co Prices $350 Million Stock Offering

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/LFSC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":42.6071,"timestamp":1791576000000,"preClose":41.675,"halted":0,"volume":561,"hourTrading":{"tag":"盘后","latestPrice":42.68,"preClose":42.6071,"latestTime":"16:10 EDT","volume":1,"amount":42.6071,"timestamp":1791576604081,"change":0.0729,"changeRate":0.001711,"amplitude":0},"delay":0,"changeRate":0.022365926814637206,"floatShares":2777035,"shares":2777035,"eps":0,"marketStatus":"Market Closed","change":0.9321,"latestTime":"10-09 16:00:00 EDT","open":42.515,"high":42.68,"low":42.515,"amount":23883,"amplitude":0.003959,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":41.675,"sharesOutstanding":2657035,"nav":41.68,"aum":115746818.8,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":42.68,"preClose":42.6071,"latestTime":"16:10 EDT","volume":1,"amount":42.6071,"timestamp":1791576604081,"change":0.0729,"changeRate":0.001711,"amplitude":0},"volumeRatio":0.358558},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2777035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.358558,"shares":2777035,"dividePrice":0,"high":42.68,"amplitude":0.003959,"preClose":41.675,"low":42.515,"week52Low":29.4441,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":42.6071,"eps":0,"divideRate":0,"volume":561,"delay":0,"ttmEps":0,"open":42.515,"prevYearClose":36.6147,"prevWeekClose":43.401,"prevMonthClose":44.5697,"prevQuarterClose":44.5697,"fiveDayClose":43.401,"twentyDayClose":45.3275,"sixtyDayClose":44.9054},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674785642","title":"Teva announces FDA approval for Weltruza","url":"https://stock-news.laohu8.com/highlight/detail?id=2674785642","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674785642?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:05","pubTimestamp":1791543924,"startTime":"0","endTime":"0","summary":"Teva (TEVA) announced that the FDA has approved Weltruza for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-for-weltruza-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-for-weltruza-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","LFSC","TEVA","MRNY","GDOC","BK4588","BK4566","BK4007","IYH","XLVX","BBP","BK4596","IDNA","MEDI","TECB","BMED","LABU","NVIB","BK4557","IBB","LU2324357040.USD","FRTY","BK4584","IEIH","SYNB","GNMX","TBXU","RSPH","LU1983299246.USD","PINK","BK4559","BK4585","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674000684","title":"Guardant announces Europe approval of Guardnat360 CDx as Etcamaha companion","url":"https://stock-news.laohu8.com/highlight/detail?id=2674000684","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674000684?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:15","pubTimestamp":1791490537,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced that Guardant360 CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a comp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-announces-europe-approval-of-guardnat360-cdx-as-etcamaha-companion-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-announces-europe-approval-of-guardnat360-cdx-as-etcamaha-companion-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","GNOM","LU0889565916.HKD","HELX","EKG","BK4551","GNMX","LU0109394709.USD","PTH","GH","FFOX","BK4588","BK4585","LU0320765992.SGD","BK4535","BK4196","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674000800","title":"Guardant Health Wins EU CE Mark for Guardant360 CDx as Camizestrant Companion Diagnostic in ER-Positive Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2674000800","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674000800?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:12","pubTimestamp":1791490344,"startTime":"0","endTime":"0","summary":"Guardant Health wins EU CE mark for Guardant360 CDx as camizestrant companion diagnostic in ER-positive breast cancerGuardant Health secured EU CE-marking for Guardant360 CDx as a companion diagnostic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL7WpmQr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","GNMX","GNOM","PTH","BK4585","LFSC","BK4588","BK4551","BK4196","EKG","GDOC","FFOX","BK4535","HELX","LU0109394709.USD","LU0889565916.HKD","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674802000","title":"Guardant Health Announces Approval in Europe of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Er-Positive Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2674802000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674802000?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:12","pubTimestamp":1791490320,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nTUA8LV3XK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0784385840.USD","LU0345777659.USD","LU2023251221.USD","LU0997586515.USD","LU2237443622.USD","LU0661504455.SGD","LU0345777147.USD","EKG","HELX","AZN.UK","LU0029864427.USD","LU0960981461.USD","LU0011850046.USD","LU0784383803.USD","LU0757432116.USD","FFOX","GDOC","IE00B3T34201.USD","LU1153585028.USD","LU1261432733.SGD","LU2125909247.SGD","GH","GNMX","LU1153584641.USD","LU1323610961.USD","LU0949170426.SGD","LU1496350171.SGD","LU0827474353.SGD","LU1863844749.USD","IE00BJT1NW94.SGD","LU0949170772.SGD","LU0823399737.USD","LU1481599808.USD","LU1267930813.SGD","LFSC","LU1923622614.USD","LU2539964713.USD","LU1015430645.USD","LU1057294990.SGD","LU1989772923.USD","03165","LU0972486137.USD","LU0882574055.USD","LU0058720904.USD","LU2293690249.USD","PTH","GNOM","LU0823416689.USD","LU0211326755.USD","LU0526926950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674007701","title":"Guardant Health to Report Q3 2026 Financial Results After Market Close, Host Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2674007701","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674007701?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:05","pubTimestamp":1791489926,"startTime":"0","endTime":"0","summary":"Guardant Health to report Q3 2026 financial results after market close, host conference callGuardant Health schedules third-quarter 2026 results release for Nov. 5, 2026, following the market close.Ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDLWjfQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","PTH","BK4551","BK4535","BK4585","GNOM","HELX","LU0320765992.SGD","FFOX","GDOC","BK4588","LU0109394709.USD","EKG","GNMX","BK4196","GH","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673504724","title":"Is Spyre Therapeutics (SYRE) Fully Priced Following Its $350 Million Equity Raise?","url":"https://stock-news.laohu8.com/highlight/detail?id=2673504724","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673504724?lang=en_us&edition=fundamental","pubTime":"2026-10-08 10:45","pubTimestamp":1791427550,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) has moved into focus after completing a US$350.0 million follow on equity offering at US$85 per share, adding 4,117,648 common shares at a discount to prior trading.\nRecent trading shows that momentum in Spyre Therapeutics has cooled in the short term, with the 7 day share price return down 9.2%, the 30 day move lower by 9.1%, and the 90 day share price performance down 18.1%. This is occurring even though the year to date share price return is 164.4% and the 1 year...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/is-spyre-therapeutics-syre-fully-priced-following-its-350-mi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/is-spyre-therapeutics-syre-fully-priced-following-its-350-mi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LFSC","BK4585","BK4588","SYRE","REZ","BK4215","BK4139","EQR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011517","title":"Novartis announces FDA approval of Rhapsido for symptomatic dermographism","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011517","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011517?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:50","pubTimestamp":1791388212,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that the Food and Drug Administration approved Rhapsido as the first treatment for adults with symptomatic dermographism i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-announces-fda-approval-of-rhapsido-for-symptomatic-dermographism-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-announces-fda-approval-of-rhapsido-for-symptomatic-dermographism-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","MEDX","LU0070302665.USD","XLVX","NVIB","LU0208291251.USD","IE00BJT1NW94.SGD","BMED","LFSC","IYH","LABU","FRTY","BK4585","BK4588","BBP","BK4007","MEDI","IEIH","TECB","GNMX","PINK","BK4578","MRNY","LU0320765489.SGD","IE0002141913.USD","IBB","SYNB","TBXU","GDOC","IDNA","BK4532","MRNX","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","LU0211331839.USD","RSPH","NVS","IE00BJJMRZ35.SGD","PPH","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673118620","title":"Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673118620","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673118620?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:45","pubTimestamp":1791387900,"startTime":"0","endTime":"0","summary":"In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible ur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376686/0/en/novartis-rhapsido-remibrutinib-receives-fda-approval-as-first-treatment-for-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IAI","LU1064131342.USD","LU1720051108.HKD","LU0210528500.USD","LU1668664300.SGD","LU0528227936.USD","LU0267386448.USD","MEDI","PINK","LU2089284900.SGD","PSCH","KBWB","LU2357305700.SGD","LU2487616109.SGD","SD","TBXU","TECB","BK4581","LFSC","MRNX","LABU","BK4585","LU1720051017.SGD","LU0390134368.USD","NVIB","FRTY","IBB","BK4504","LU0912757837.SGD","BBP","LU1791710582.SGD","IEIH","LU2028103732.USD","BMED","MRNY","XLVX","LU1244550221.USD","LU0795875169.SGD","SYNB","RSPH","LU2023251221.USD","GDOC","LU2264538146.SGD","IE00BZ1G4Q59.USD","LU0106831901.USD","IE00B3S45H60.SGD","LU1989772840.SGD","IYH","GNMX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673162670","title":"Guardant Health is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2673162670","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673162670?lang=en_us&edition=fundamental","pubTime":"2026-10-07 22:43","pubTimestamp":1791384180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4196","LU0889565916.HKD","FFOX","LU0320765992.SGD","LFSC","BK4551","PTH","BK4585","GDOC","GH","EKG","HELX","GNMX","BK4535","LU0109394709.USD","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673013128","title":"LivaNova Price Target Announced at $105.00/Share by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2673013128","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673013128?lang=en_us&edition=fundamental","pubTime":"2026-10-07 21:05","pubTimestamp":1791378300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LIVN/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LFSC","LU2065171402.SGD","LIVN","LU2065169927.USD","BK4082","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673937340","title":"StemRIM Wins U.S. Patent for Stem Cell Gene Therapy Targeting Rare Skin Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2673937340","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673937340?lang=en_us&edition=fundamental","pubTime":"2026-10-07 14:55","pubTimestamp":1791356112,"startTime":"0","endTime":"0","summary":"StemRIM Inc. ( ($JP:4599) ) has shared an announcement. StemRIM Inc. has secured a U.S. patent for a stem cell gene therapy technology, development...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/stemrim-wins-u-s-patent-for-stem-cell-gene-therapy-targeting-rare-skin-disease?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/stemrim-wins-u-s-patent-for-stem-cell-gene-therapy-targeting-rare-skin-disease?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBBQ","CNCR","SYNB","IBB","BK4585","TBXU","LFSC","BK4588","GNOM","FBT","USRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673498095","title":"Should New FILSPARI Data Require Action From Travere Therapeutics Stock Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2673498095","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673498095?lang=en_us&edition=fundamental","pubTime":"2026-10-07 14:23","pubTimestamp":1791354237,"startTime":"0","endTime":"0","summary":"Travere Therapeutics reported new FILSPARI data at ASN Kidney Week 2026, with SPARTAN, DUPLEX and PROTECT results underscoring efficacy, renal protection signals and safety in IgA nephropathy and FSGS, alongside real world and molecular findings.\nThe USPTO Notice of Allowance for a new FSGS use patent and an issued IgAN patent extend FILSPARI method-of-use protection into 2037, which matters for Travere Therapeutics’ pricing power, competitive position and long term planning around its lead...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/should-new-filspari-data-require-action-from-travere-therape","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/should-new-filspari-data-require-action-from-travere-therape","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FFTY","BK4211","LU2324357040.USD","LENZ","BK4139","LFSC","BK4007","TVTX","BK4539","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673006553","title":"LivaNova initiated with an Overweight at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2673006553","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673006553?lang=en_us&edition=fundamental","pubTime":"2026-10-07 04:31","pubTimestamp":1791318699,"startTime":"0","endTime":"0","summary":"Barclays analyst Christopher Pasquale initiated coverage of LivaNova (LIVN) with an Overweight rating and $105 price target The firm rolled out cov...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/livanova-initiated-with-an-overweight-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/livanova-initiated-with-an-overweight-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065171311.SGD","BK4082","LU2065169927.USD","LIVN","LFSC","LU2065171402.SGD","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673633350","title":"Update: Spyre Shares Fall After Pricing $350 Million Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2673633350","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673633350?lang=en_us&edition=fundamental","pubTime":"2026-10-07 03:56","pubTimestamp":1791316569,"startTime":"0","endTime":"0","summary":"(Updates with the latest stock price movement in the headline and the first paragraph.)Spyre Therapeutics (SYRE) shares fell over 13% in Tuesday trading after the company priced an underwritten public","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LFSC","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673068758","title":"Guardant Health Inc Stock (GH) Moved Down by 8.27% on Oct 6: What Investors Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2673068758","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673068758?lang=en_us&edition=fundamental","pubTime":"2026-10-07 03:15","pubTimestamp":1791314128,"startTime":"0","endTime":"0","summary":"• Guardant Health shares dropped due to profit-taking after a multi-month rally.\n• Ongoing unprofitability and high valuation multiples triggered intense selling pressure.\n• The company reported $982.02M in annual revenue and a net profit of $-416.28M.","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262202416-market-movers-gh-20261006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4585","BK4551","BK4196","LU0889565916.HKD","BK4588","GH","LU0320765992.SGD","GNOM","BK4535","EKG","FFOX","HELX","PTH","LFSC","GDOC","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673527730","title":"Guggenheim Remains a Buy on Cogent Biosciences (COGT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673527730","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673527730?lang=en_us&edition=fundamental","pubTime":"2026-10-06 23:05","pubTimestamp":1791299120,"startTime":"0","endTime":"0","summary":"Guggenheim analyst maintained a Buy rating on Cogent Biosciences today and set a price target of $52.00. The word on The Street in general, suggest...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-cogent-biosciences-cogt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-cogent-biosciences-cogt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COGT","CANC","BK4139","BK4505","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673542070","title":"Spyre Therapeutics falls -8.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673542070","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673542070?lang=en_us&edition=fundamental","pubTime":"2026-10-06 22:07","pubTimestamp":1791295626,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) is down -8.4%, or -$7.80 to $84.92. Published first on TheFly – the ultimate source for real-time, market-moving breaking...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-falls-8-4-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-falls-8-4-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SYRE","BK4139","LENZ","LFSC","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673055180","title":"U.S. Stocks on the MOVE-MYR Group, Spyre Therapeutics, AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2673055180","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673055180?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:37","pubTimestamp":1791286654,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-MYR Group, Spyre Therapeutics, AMDOct 6 (Reuters)-US stock index futures rose on Tuesday as Treasury yields dipped from multi-year highs and oil prices retreated, offering","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nL6N45S0QE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211326839.USD","IE000SO60NU8.SGD","LTL","IE00BJTD4V19.USD","IE0009356076.USD","IVEP","LU0133085943.USD","LU0128525929.USD","AIS","LU0276348264.USD","LU2092627202.USD","LU0211331839.USD","IE00BMPRXR70.SGD","LU2250418816.HKD","AMUU","BK4612","LU0784384876.USD","LU0980610538.SGD","LU0127658192.USD","HK0000532082.HKD","LU2381873111.SGD","CNAV","BK4077","LU0979878070.USD","LU0353189763.USD","LU2360106780.USD","LU1267930490.SGD","LU2097829019.USD","LU1974910355.USD","LU2355687059.USD","IE0002270589.USD","NLR","LU2211815571.USD","NKE","LU1366333091.USD","LU2954938101.SGD","LU1196500208.SGD","IE0004445239.USD","LU2125154778.USD","LU0823421416.USD","VOX","LU1093756325.SGD","LU2242650005.HKD","LU0267386448.USD","LU1989772923.USD","LU2125154935.USD","LU0251132253.USD","LU0314106906.USD","LU2505996681.GBP","SGXZ51526630.SGD","LU0949170772.SGD","LU1244550494.USD","IE00BLSP4452.SGD","LU1935042991.SGD","LU0130103400.USD","GOGL","LU0642271901.SGD","IE000F7OJYX1.SGD","LU1429558221.USD","SYRE","LU2491049909.HKD","GOOL","LU1935043452.HKD","LU0097036916.USD","LU0061474960.USD","MYRG","LU2087625088.SGD","SKYY","LU0302445910.USD","BK4575","OGIG","STYL","LU1868836914.USD","LU2860962120.EUR","IE000MB6IJN5.SGD","LU2054465674.USD","LU0648000940.SGD","IE00BD4GTT62.SGD","LU2023250330.USD","LU0158827781.USD","LU0314104364.USD","LU0792757196.USD","IE0004086264.USD","LU2271345857.HKD","LU0289960550.SGD","LU2087621335.USD","LU2750360997.AUD","LU0070302665.USD","LU1923622614.USD","SG9999015341.SGD","LU1003077747.HKD","IE00BBT3K403.USD","XLU","LU0742534661.SGD","LU2326559502.SGD","LU0784383803.USD","WISE","LU0345770308.USD","LU0949170426.SGD","TEK","LU0345769128.USD","GOOW","LU0943347566.SGD","SAMD0main","LU1043141123.HKD","LU0256863902.USD","LU1935043536.SGD","LU2168564495.EUR","LU1066053197.SGD","LU1221951046.USD","IETC","LU1571399168.USD","LU2264538146.SGD","SOXX","LU2471134879.HKD","SG9999001424.SGD","LU2063271972.USD","LU2077746001.SGD","LU0061475181.USD","LU1880398554.USD","BK4141","BK4023","LU0353189680.USD","BAI","IE00BJLML261.HKD","LU2247934214.USD","IE0000B7K699.USD","LU0170899867.USD","LU1645745479.HKD","LU1815333072.USD","IE00BDCRKT87.USD","BK4503","LU1852331112.SGD","IE00BQXX3D17.EUR","LU0048584097.USD","LU0048573561.USD","LU0868494617.USD","IE00BN8TJ469.HKD","LU1585245621.USD","LU0726765562.USD","LU0070217475.USD","LU2750360641.GBP","LU1670628061.USD","LU2125909247.SGD","IE0004091025.USD","AMDW","LU0234572021.USD","LU0211326755.USD","BK4129","LU0354030438.USD","BK4139","LU2102340556.USD","LU1430594728.SGD","LU2362541273.HKD","LU1400636491.USD","LU0310800379.SGD","SG9999015986.USD","LU1951200564.SGD","IE00BLSP4239.USD","LU2384288077.EUR","IE000WAW04H5.SGD","LU1064131342.USD","LU1153585028.USD","IE00B1XK9C88.USD","IE00B5949003.HKD","LU2028103732.USD","BK4574","LU2111349929.HKD","LU2746668974.SGD","LU2471134952.CNY","LU2065171311.SGD","LU2236285917.USD","LU0143551892.USD","FUTY","LU0942090050.USD","LU1699723380.USD","LU0109392836.USD","CHAT","IE00BSNM7G36.USD","LU0964807845.USD","LU1674673428.USD","LU0345768153.USD","LU0082616367.USD","LU1201861249.SGD","LU2290526834.HKD","LU1548497426.USD","UTES","SGXZ80539844.SGD","BK4576","LU0823434740.USD","AMYY","LU0648001328.SGD","LU1202635105.USD","LU2092937148.SGD","PSI","LU1496350171.SGD","CEGX","LU1868837136.USD","BK4573","LU1791710400.SGD","LU2065170008.USD","LU0823421333.USD","GXPC","LU0056508442.USD","LU1116320737.USD","LU1400636657.SGD","LU0477156797.USD","LU0208291251.USD","LU0708995401.HKD","LU1989772840.SGD","BK4532","LU1989764664.SGD","LU2237438978.USD","LU2430703095.HKD","WUGI","IE00BMPRXQ63.HKD","LU1316542783.SGD","LU0553294199.USD","LU0289961442.SGD","LU2458330243.SGD","LU0889565833.HKD","LU0106261372.USD","DAMD","LU0130102774.USD","LU1032955483.USD","LU1989764748.USD","LU0053671581.USD","LU0225283273.USD","LU1280957306.USD","AMDL","IE00BJTD4N35.SGD","LU1119994496.HKD","LU2756315318.SGD","IE00BZ1G4Q59.USD","HK0000304797.USD","IE00BKVL7J92.USD","LU0320765059.SGD","AMDY","SGXZ99366536.SGD","LU1670756490.USD","LU0898699433.AUD","IE000BZT7R73.USD","LU0494093205.USD","SG9999015358.SGD","UPW","IE0001KFT4U8.USD","LU1839511570.USD","LU0106261612.USD","LU1267930227.SGD","QQQA","LU1066051225.USD","LU2456880835.USD","BK4605","LU1935042215.USD","HK0000914660.USD","LU0316494557.USD","LU2168564065.EUR","LU0476273544.USD","LU0052756011.USD","LU0787776722.HKD","LU1201861165.SGD","SG9999015978.USD","LEGR","LU2592432038.USD","GGLL","BK4585","IE00BK4W5M84.HKD","LU0157215616.USD","LU0256863811.USD","BK4588","LU2471134796.USD","LU1923623000.USD","LU2360032135.SGD","SG9999014880.SGD","GGLS","LU1917777945.USD","GAMR","LU1803068623.USD","LU0689472784.USD","EFIV","LU1145028129.USD","LU1400636574.HKD","FAI","LU1235294995.USD","LU2491050154.USD","LU1267930813.SGD","SG9999018865.SGD","LU0211328371.USD","LU0345769631.USD","BK4550","LU2023251221.USD","ILDR","LU0417517546.SGD","LU0323591593.USD","LU1621767737.EUR","CMAG","BK4543","LU1894683264.USD","LU1496350502.SGD","LU0683600562.USD","LU0889566641.SGD","LU2125909593.SGD","LU2265009873.SGD","LU2746668461.USD","LU0672654240.SGD","SG9999018857.SGD","LU0011850046.USD","LU0496365809.HKD","LU1629891620.HKD","LU0528227936.USD","IE00B19Z3581.USD","BK4529","IE00BDRTCR15.USD","LU1232071149.USD","LU2089283258.USD","LU1935042488.USD","IE00B1BXHZ80.USD","LU0426417589.USD","LU2458330169.SGD","LU0823434583.USD","LU0466842654.USD","LU1242518857.USD","LU2417539215.USD","LU0265550359.USD","LU1935043023.USD","LU2362540622.SGD","SG9999002224.SGD","LU2543165471.USD","AMDU","LU0511384066.AUD","LU0976567544.SGD","LU1804176565.USD","GOOGL","GOOY","LU0029864427.USD","BK4598","LU2108987350.USD","LU0251131958.USD","BK4606","LU0203345920.USD","LU1815336091.USD","BK4533","SG9999015945.SGD","LU0094547139.USD","FTXL","LU0345768740.USD","LU1267930730.SGD","LU2347655156.SGD","LU2430703178.SGD","IE00BK4W5L77.USD","LU2602419157.SGD","LU2461242641.AUD","IE00B19Z9505.USD","LU2065169927.USD","AMDC","LU2361044949.HKD","IE00BMPRXN33.USD","LU2404859741.USD","LU0211327993.USD","LU0138981039.USD","LU1823568750.SGD","LU0128525689.USD","LU1267930573.SGD","LU0069063385.USD","LU2491050071.SGD","LU0130518102.USD","LU1221951129.SGD","LU1435385759.SGD","LU1720051108.HKD","LU0426412945.USD","LU1621768206.USD","IE00B7SZLL34.SGD","LU1633808545.USD","LU0234570918.USD","LU1861220033.SGD","LU2023250843.SGD","SMHX","LU0882574139.USD","LU0708994859.HKD","LU1880398471.USD","LU0130517989.USD","LU0274383776.USD","LU0354030511.USD","LU0957808578.USD","LU0738911758.USD","LU2098885051.SGD","LU0187121727.USD","BK4561","LU0198837287.USD","LU0096362180.USD","LU1732799900.SGD","LU0310799852.SGD","BK4602","LU2065731478.USD","LU1732800096.USD","LU2362541513.USD","TRFK","LU2244417387.USD","IE00BQXX3F31.USD","SG9999014914.USD","IE00B19Z8W00.USD","JXI","LU1951198990.SGD","LU2097344431.USD","LU1868836591.USD","LU1621767810.EUR","SG9999014898.SGD","SG9999017495.SGD","LU0345774391.USD","TRUC","SG9999014567.USD","USXF","LU1914381329.SGD","LU1066051811.HKD","LU2106854487.HKD","BK4581","GOOP","LU0080751232.USD","LU2462591350.SGD","LU0312595415.SGD","LU1093756168.USD","LU0348723411.USD","LU0690374615.EUR","LU2191332357.HKD","IE00BKDWB100.SGD","IE00BD4GTW91.USD","LU0557290698.USD","LU0251142724.SGD","IE00BYQQ9H92.USD","LU0820561818.USD","LU2023250504.SGD","LU0868494708.USD","LU1720051017.SGD","BK4512","TRUU","LU0784385170.HKD","LU0215105999.USD","LU0957791311.USD","GOU","LU1815336760.USD","LU2089284900.SGD","LU1551013425.SGD","TTEQ","LU2433249047.HKD","BK4592","LU0472753341.HKD","LU2462591277.SGD","LU1778281490.HKD","LU2168564149.EUR","SG9999014906.USD","SG9999015952.SGD","CEG","URAN","LU2213496289.HKD","LU2420271590.USD","ARTY","LU1084165304.USD","LU2462157665.USD","XNTK","LU1043141396.HKD","LU1621768115.EUR","IE00BD4GTV84.USD","LU1121112475.USD","SG9999014559.SGD","LU0820562030.AUD","LU0124676726.USD","LU0265550946.USD","AMD","LU0395794307.EUR","IE00B19Z8X17.USD","LU0320765489.SGD","IE00B19Z3B42.SGD","LU1303367103.USD","LU0057025933.USD","FRSH","LU0109391861.USD","BK4514","GB00B4QBRK32.GBP","LU1059921491.USD","LU0994945656.USD","LU0661504455.SGD","IE00BHPRN162.USD","LU0912757837.SGD","LU0158827948.USD","LU1894683348.USD","LU1988902786.USD","SG9999002232.USD","LU0690374961.EUR","VPU","LU1366192091.USD","LU0719512351.SGD","LU0444971666.USD","LU2361045086.USD","GOOX","SG9999000418.SGD","IE00BWXC8680.SGD","LU0345770993.USD","HK0000819398.USD","LU0096364046.USD","XLC","LU0795875086.SGD","LU2360107168.USD","BK4554","LU0640476718.USD","LU0784385840.USD","LU2931357623.SGD","SG9999014542.SGD","LU1144417596.USD","BK4614","LU0174119429.USD","LU0345774631.USD","LU2756315664.SGD","AMDS","IE00BD6J9T35.USD","LU0149725797.USD","LU1244550221.USD","LU1791710582.SGD","LU0210533765.USD","LU0077335932.USD","LU1868836757.USD","LU2168563687.JPY","SG9999014575.USD","LFSC","LU2404859667.USD","SMH","LU0210536198.USD","LU0823411888.USD","LU0390134368.USD","LU2097344357.USD","SNPE","SGXZ81514606.USD","CQTM","BK4196","SGXZ44715902.SGD","LU1066051498.USD","LU2896262040.SGD","IE00BKPKM429.USD","IE0034235295.USD","IE00BFMHRM44.USD","LU1718418525.SGD","LU2999663052.SGD","LU1670627923.USD","LU0477156953.USD","LU2065171402.SGD","FCOM","BK4534","LU0107464264.USD","HK0000304805.HKD","BK4538","GB00B4LPDJ14.GBP","LU1868837300.USD","LU0054578231.USD","LU2242649171.HKD","LU0786609619.USD","LU2275660780.HKD","BK4527","LU1674673691.USD","IE00BFXG0V08.USD","HK0000914686.HKD","SOXY","IE0034235303.USD","LU0689626769.HKD","LU2168564222.USD","LU2471134523.USD","LU0154236417.USD","LU1242518931.SGD","LU1261432733.SGD","LU0081259029.USD","CHPS","IDU","LU0985320562.USD","LU1861558580.USD","LU1301847155.USD","OPCH","BK4146","BK4081","LU2403377893.USD","LU1046421795.USD","LU2505996509.AUD","BK4566","LU1551013342.USD","XDAT","LU0006306889.USD","BK4558","LU0545039389.USD","LU1803068979.SGD","LU1861215975.USD","LU0757428866.USD","LU0342679015.USD","LU0310800965.SGD","IE0034235188.USD","LU1244550577.SGD","LU0289739343.SGD","LU0795875169.SGD","METV","SGXZ31699556.SGD","LU0820561909.HKD","LU2089985449.USD","LU2430703251.USD","LU0203347892.USD","AMDG","LU2361044865.SGD","LU0444973449.USD","AMDD","LU0061474705.USD","LU1323610961.USD","LU1506573853.SGD","AIQ","LU1861559042.SGD","LU1116320901.HKD","LU2347655073.USD","LU0175139822.USD","IE00BYXW3230.USD","LU1642822529.SGD","LU2357305700.SGD","BK4579","IE00BQXX3C00.GBP","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673558750","title":"Spyre Therapeutics Slips on $350 Mln Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2673558750","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673558750?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:16","pubTimestamp":1791285378,"startTime":"0","endTime":"0","summary":"BUZZ-Spyre Therapeutics slips on $350 mln share sale** Shares of Spyre TherapeuticsSYRE.Odown 4.1% at $88.90 premarket after $350 mln follow-on priced** Biotech firm late Mon announced ~4.1 mln shares","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nL6N45S0PG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673030198","title":"Spyre Therapeutics Shares Slip 1.7% Premarket After Co Prices $350 Million Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2673030198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673030198?lang=en_us&edition=fundamental","pubTime":"2026-10-06 17:41","pubTimestamp":1791279699,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nFWN45R1J0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}